Anish Koka - Why Vinay Prasad Didn’t Last at the FDA

In this episode of Science from the Fringe, host Bryce Nickels speaks with cardiologist and medical commentator Dr. Anish Koka about his recent article examining the forces that led to physician-scientist Vinay Prasad’s departure from the U.S. Food and Drug Administration (FDA). They discuss how Prasad’s efforts to strengthen evidentiary standards for drug approvals quickly ran up against powerful political, financial, and institutional interests. The conversation explores how his brief tenure became a case study in the difficulty of reforming institutions where scientific standards, patient desperation, political pressure, and financial incentives collide.As Anish explains, Vinay Prasad is an unusually independent thinker within academic medicine who built a reputation challenging weak evidentiary standards for drug approvals long before entering government. Once at the FDA, he attempted to raise those standards—particularly for vaccines and costly therapies approved on limited or indirect evidence. Those efforts quickly triggered backlash from pharmaceutical companies, investors, patient advocacy groups, biotech media, and political actors with stakes in the approval pipeline.Anish walks through a detailed timeline of the flashpoints that defined Prasad’s short tenure: disputes over gene therapies for rare diseases, conflicts with companies such as Sarepta, Moderna, and UniQure, and broader debates about how regulators should weigh desperate patient demand against uncertain clinical evidence. He explains how controversial trial designs—such as reliance on historical controls or small datasets—can allow extremely expensive treatments to reach the market without clear proof they improve patient outcomes. In his view, Prasad’s push to tighten evidentiary standards exposed deeper structural problems in the drug-approval system.The conversation also explores the political and media dynamics surrounding Prasad’s tenure, including accusations that he created “chaos” at the agency, personal attacks, and media leaks that intensified pressure on FDA leadership. Bryce and Anish argue that Prasad’s willingness to publicly take responsibility for regulatory decisions—and to challenge entrenched interests—made him an unusually rare figure in Washington.The episode concludes with a broader discussion about incentives in drug regulation: the influence of pharmaceutical profits, the vulnerability of rare-disease communities to exploitation, and whether meaningful reform of the FDA’s approval process is possible from within the current system. Despite Prasad’s departure, Anish argues that his brief tenure exposed important weaknesses at the intersection of science, regulation, industry, and media.(recorded March 8, 2026)Timestamps00:31 – Introducing Anish Koka and the Vinay Prasad story02:12 – Why Prasad’s FDA appointment was surprising03:20 – Prasad’s background and COVID-era break from consensus04:24 – The core issue: declining evidentiary standards at FDA06:41 – Prasad’s integrity and inevitable clash with the system09:57 – Was Prasad set up?12:08 – Why Peter Marks mattered politically13:19 – Prasad’s new vaccine approval framework14:18 – Sarepta and weak evidence in rare disease drugs17:13 – Media leaks and the role of Stat News19:33 – Marty Makary backs Prasad20:05 – “Bad politics” or principled regulator?21:58 – The Moderna dispute over vaccine evidence23:51 – Accountability and why Prasad stood out27:49 – Personal attacks and mounting pressure28:09 – The UniQure controversy30:53 – What a sham control is33:55 – The problem with historical controls36:00 – Who decides trial matching?38:00 – Media narratives of “chaos” at FDA40:19 – Political pressure from Congress42:39 – The chain of events leading to Prasad’s exit45:04 – Rare disease desperation and potential exploitation49:03 – What Prasad exposed about the FDA ecosystem50:45 – The rare disease approval loophole53:45 – Investors, incentives, and distorted evidence54:13 – Why few would want Prasad’s job54:39 – Final reflections on integrity and institutional pressureintro and outro by Tess Parks Get full access to Science From the Fringe at sciencefromthefringe.substack.com/subscribe